NIBL Ace Capital to invest in H Medical & Diagnostics

By A Staff Reporter, Kathmandu, Nov. 29: NIBL Ace Capital Limited, an investment bank in Nepal, and H. Medical and Diagnostic Private Limited (HMDL), a division of Dugar Healthcare, signed a definitive investment agreement on Sunday.

Shivanth Bahadur Pandé, Chief Executive Officer of NIBL Ace and Abhishek Dugar, Vice Chairman and CEO of H. Medical and Diagnostic Private Limited (HMDL) have signed on the agreement on behalf of their respective institution.

The HMDL in collaboration with Tata Medical and Diagnostics, a wholly owned subsidiary of TATA Group, India’s largest salt to software conglomerate, has grown to become one of the leading companies in medical tech and diagnostic sectors which develops, produces and markets futuristic diagnostic products including medical equipment, reagents, pharmaceuticals drugs and other products, according to a press statement of NIBL Ace Capital.

The HMDL, which was established in 2021, amidst the COVID-19 pandemic, quickly created a niche for itself by importing affordable PCR kits manufactured by Tata Medical and Diagnostics. 

It captured major market share in Nepal by building a highly recognisable brand portfolio with robust sales of COVID PCR kits and reagents. 

The HMDL also introduced a Tata manufactured mobile diagnostic van which can access remotest of the areas in Nepal’s mountainous regions to carry out diagnostic tests.

With the impressive objective of providing affordable healthcare all over Nepal, the company plans to establish and operate full-fledged manufacturing units to produce diagnostic and reagents products in Nepal, apart from setting up high tech futuristic diagnostic centers all over the country and launch different products and services in collaboration with TATA medical and diagnostics, India. 

Their entire business focus would be integrating futuristic and emerging technologies into healthcare. 

They will also work in tandem with other diagnostic labs and hospitals to provide integrated and affordable healthcare solutions to the masses, read the press statement.